View all veterinary jobs
CharcoPet is a ready-to-use oral gel formulated with 50% activated charcoal and marine-derived polysaccharides.
Forte says Charcopet has a high concentration of activated charcoal per ml, which reduces the volume needed and minimises handling stress.
It's supplied in a 2 x 30ml dial-dose syringes, with each syringe suitable for up to 15 kg bodyweight, used at 2 ml/kg bodyweight orally, repeatable every 4–6 hours if clinically required.
Dr Lucy Chadwick MVB ACIM CMktr MRCVS, Global Partnerships Manager & Head of Technical Services at Forte Healthcare said: “CharcoPet represents a major step forward in veterinary care, offering practitioners a fast, precise, and reliable solution when faced with suspected or confirmed cases of toxin or medication ingestion."
https://fortehealthcare.com/product/charcopet/
Ficoxil contains the active ingredient firocoxib, an NSAID from the coxib class, known for its analgesic, anti-inflammatory, and antipyretic properties.
Ficoxil is available in two strengths, 57 mg and 227 mg in packs of 30.
The tablets, which are presented in presented in a divisible and blister-perforated form, are hypoallergenic, gluten-free, and come in a beef flavour of animal-free origin.
Ficoxil is available now from all major veterinary wholesalers.
https://www.fortehealthcare.com/product/ficoxil
The company says that recent supply issues have been due to 'incredible' demand for Reconcile since it was launched in the UK in 2022, which greatly surpassed expectations.
Dr Lucy Chadwick, Head of Technical Services & Marketing at Forte Healthcare Ltd said: “We realise that the recent supply issues have been very inconvenient so we thank all of our customers for their patience and support during this challenging time.
"We are confident that our supply issues to date have been resolved and that we have enough stock going forward to meet market demand.“
www.reconcilefordogs.com
Dexafast is an injectable corticosteroid with potent, medium-acting, anti-inflammatory activity, indicated for the treatment of a range of inflammatory and allergic conditions in both small and large animal clinical practice.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Dexafast 2mg/ml is an excellent addition to our range. This formulation of dexamethasone is used across many species on a daily basis, and Dexafast 2mg/ml gives vets a high-quality presentation of a staple medicine."
Dexafast is available in a 50ml bottle.
For further information, contact your local Forte Territory Manager, visit: https://www.fortehealthcare.ie/product/dexafast-uk-only, or email: enquiries@fortehealthcare.com.
On 23rd October, Dr Hannah Capon MA Vet MB MRCVS will present 'OA management: more than just drugs', in which she will consider how best to manage canine osteoarthritis in first opinion practice and offer practical tips on how veterinary surgeons and nurses can help owners manage the condition better.
On 6th November, Dr Zoe Belshaw MA Vet MB PhD Cert SAM Dip ECVIM-CA AFHEA MRCVS (pictured right) will present 'Increasing compliance in OA treatment', during which she will discuss some of the reasons behind poor compliance and strategies to improve compliance by owners of dogs with osteoarthritis.
Forte Healthcare’s head of technical services and marketing, Dr Lucy Chadwick said: "We are delighted to have two well-recognised experts to deliver these webinars and we’ve made sure that they will be as equally relevant for vet nurses as they are for practising vets.
"For anyone who cannot join the live screenings, the webinars will be made available to watch on demand for a limited time after they are shown."
To register for the webinars, visit: www.fortehealthcare.com/oa-2018